| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Biology, Immunology, Cytokines |
Second Department of Medicine, Okayama University Medical School, Okayama 700-8558 [A. H., K. K., H. U., H. Y., M. T., M. H.]; and Diagnostic Science Division, Shionogi Biomedical Laboratories, Shionogi & Co., Ltd., Osaka 566-0022 [T. K.], Japan
Loss of expression of HLA class I antigens has been demonstrated in a wide variety of tumors and is considered to be one of the mechanisms whereby tumors escape T-cell surveillance. Genomic DNA of MHC class I/II molecules in seven lung cancer cell lines was investigated and compared with that in peripheral blood mononuclear cells. In three cell lines, OU-LC-A1, OU-LC-A2, and OU-LC-AS1, a loss of HLA haplotype was observed. Aberrations of HLA class I/II in tumor cell lines should be considered when MHC-restricted phenomena in vitro models are assessed and clinical use of tumor vaccination in vivo is considered.
This article has been cited by other articles:
|
|
 |
|
  H. Norell, M. Carlsten, T. Ohlum, K.-J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, et al. Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity. Cancer Res., June 15, 2006; 66(12): 6387 - 6394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. So, M. Takenoyama, M. Mizukami, Y. Ichiki, M. Sugaya, T. Hanagiri, K. Sugio, and K. Yasumoto Haplotype Loss of HLA Class I Antigen as an Escape Mechanism from Immune Attack in Lung Cancer Cancer Res., July 1, 2005; 65(13): 5945 - 5952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Friedman, C. S. Bangur, E. J. Zasloff, L. Fan, T. Wang, Y. Watanabe, and M. Kalos Molecular and Immunological Evaluation of the Transcription Factor SOX-4 as a Lung Tumor Vaccine Antigen J. Immunol., March 1, 2004; 172(5): 3319 - 3327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Merritt, R. E. Yamada, R. G. Crystal, and R. J. Korst Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 355 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sugaya, M. Takenoyama, T. Osaki, M. Yasuda, A. Nagashima, K. Sugio, and K. Yasumoto Establishment of 15 Cancer Cell Lines From Patients With Lung Cancer and the Potential Tools for Immunotherapy* Chest, July 1, 2002; 122(1): 282 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Urosevic, M. O. Kurrer, J. Kamarashev, B. Mueller, W. Weder, G. Burg, R. A. Stahel, R. Dummer, and A. Trojan Human Leukocyte Antigen G Up-Regulation in Lung Cancer Associates with High-Grade Histology, Human Leukocyte Antigen Class I Loss and Interleukin-10 Production Am. J. Pathol., September 1, 2001; 159(3): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Dubinett, R. K. Batra, P. W. Miller, and S. Sharma Tumor Antigens in Thoracic Malignancy Am. J. Respir. Cell Mol. Biol., May 1, 2000; 22(5): 524 - 527. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
